IL239824B - Use of inos inhibitors to increase viral survival in culture - Google Patents
Use of inos inhibitors to increase viral survival in cultureInfo
- Publication number
- IL239824B IL239824B IL239824A IL23982415A IL239824B IL 239824 B IL239824 B IL 239824B IL 239824 A IL239824 A IL 239824A IL 23982415 A IL23982415 A IL 23982415A IL 239824 B IL239824 B IL 239824B
- Authority
- IL
- Israel
- Prior art keywords
- culture
- inos inhibitors
- viral yield
- increase viral
- increase
- Prior art date
Links
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750175P | 2013-01-08 | 2013-01-08 | |
| PCT/US2014/010553 WO2014110053A1 (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL239824A0 IL239824A0 (en) | 2015-08-31 |
| IL239824B true IL239824B (en) | 2019-03-31 |
Family
ID=51167323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL239824A IL239824B (en) | 2013-01-08 | 2015-07-07 | Use of inos inhibitors to increase viral survival in culture |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11299715B2 (enExample) |
| EP (3) | EP2943567B1 (enExample) |
| JP (2) | JP6534933B2 (enExample) |
| KR (1) | KR102307279B1 (enExample) |
| CN (1) | CN105008523B (enExample) |
| AR (1) | AR094389A1 (enExample) |
| AU (1) | AU2014205604B2 (enExample) |
| BR (2) | BR122020002822B1 (enExample) |
| CA (1) | CA2897444A1 (enExample) |
| DK (1) | DK2943567T3 (enExample) |
| ES (1) | ES2651763T3 (enExample) |
| HK (1) | HK1249544A1 (enExample) |
| HU (1) | HUE037482T2 (enExample) |
| IL (1) | IL239824B (enExample) |
| MX (2) | MX378877B (enExample) |
| NO (1) | NO3050055T3 (enExample) |
| RU (1) | RU2676733C2 (enExample) |
| SG (3) | SG10201806715TA (enExample) |
| TW (1) | TWI608102B (enExample) |
| WO (1) | WO2014110053A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| EP4159867A1 (en) | 2016-03-28 | 2023-04-05 | Ultragenyx Pharmaceutical Inc. | Methods of heat inactivation of adenovirus |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| EP3526321B1 (en) | 2016-10-14 | 2024-11-27 | Ultragenyx Pharmaceutical Inc. | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
| EP3601581B1 (en) | 2017-03-22 | 2025-04-30 | Ultragenyx Pharmaceutical Inc. | CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS |
| JP7218303B2 (ja) | 2017-05-09 | 2023-02-06 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | トランスフェクション試薬を生成するための拡大可能な方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CN110835622B (zh) * | 2018-08-16 | 2021-04-27 | 上海药明生物技术有限公司 | 用于调节哺乳动物细胞乳酸代谢的培养基及其应用 |
| AU2019346655B2 (en) | 2018-09-28 | 2025-03-13 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2021188449A1 (en) | 2020-03-16 | 2021-09-23 | Ultragenyx Pharmaceutical Inc. | Methods for enhancing recombinant adeno-associated virus yield |
| JPWO2023157976A1 (enExample) * | 2022-02-21 | 2023-08-24 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| RU2012335C1 (ru) | 1991-07-04 | 1994-05-15 | Уфимский научно-исследовательский институт глазных болезней | Ингибитор вируса простого герпеса |
| DK0648271T3 (da) | 1991-08-20 | 2003-07-21 | Us Gov Health & Human Serv | Adenovirusmedieret overførsel af gener til mave-/tarmkanal |
| DE69332501T3 (de) | 1992-07-31 | 2009-03-26 | The President And Fellows Of Harvard College, Cambridge | Herpesvirus impfstoffe |
| US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
| US6833271B2 (en) | 1996-12-04 | 2004-12-21 | Medi-Cult A/S | Serum-free cell culture media |
| GB9816856D0 (en) | 1998-08-03 | 1998-09-30 | Univ London | Cell lines for virus growth |
| US6783972B1 (en) * | 1998-09-22 | 2004-08-31 | University Of Florida Research Foundation | Methods for large-scale production of recombinant AAV vectors |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US7091029B2 (en) | 2002-09-23 | 2006-08-15 | Applied Genetics Technologies Corporation | High titer recombinant AAV production |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| CN100348718C (zh) * | 2005-10-18 | 2007-11-14 | 中国人民解放军军事医学科学院生物工程研究所 | 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基 |
| US8334295B2 (en) * | 2007-06-29 | 2012-12-18 | Korea Research Institute Of Chemical Technology | Pyrimidine derivatives as HIV reverse transcriptase inhibitors |
-
2014
- 2014-01-07 HU HUE14703459A patent/HUE037482T2/hu unknown
- 2014-01-07 AU AU2014205604A patent/AU2014205604B2/en not_active Ceased
- 2014-01-07 MX MX2018013366A patent/MX378877B/es unknown
- 2014-01-07 EP EP14703459.9A patent/EP2943567B1/en active Active
- 2014-01-07 DK DK14703459.9T patent/DK2943567T3/en active
- 2014-01-07 EP EP17184746.0A patent/EP3266866B1/en active Active
- 2014-01-07 TW TW103100466A patent/TWI608102B/zh active
- 2014-01-07 ES ES14703459.9T patent/ES2651763T3/es active Active
- 2014-01-07 US US14/758,785 patent/US11299715B2/en active Active
- 2014-01-07 SG SG10201806715TA patent/SG10201806715TA/en unknown
- 2014-01-07 BR BR122020002822-0A patent/BR122020002822B1/pt active IP Right Grant
- 2014-01-07 SG SG11201505333PA patent/SG11201505333PA/en unknown
- 2014-01-07 WO PCT/US2014/010553 patent/WO2014110053A1/en not_active Ceased
- 2014-01-07 BR BR112015016328-9A patent/BR112015016328B1/pt active IP Right Grant
- 2014-01-07 RU RU2015133205A patent/RU2676733C2/ru active
- 2014-01-07 EP EP19160865.2A patent/EP3521420A1/en not_active Withdrawn
- 2014-01-07 CN CN201480012376.2A patent/CN105008523B/zh active Active
- 2014-01-07 MX MX2015008861A patent/MX360470B/es active IP Right Grant
- 2014-01-07 KR KR1020157021175A patent/KR102307279B1/ko active Active
- 2014-01-07 CA CA2897444A patent/CA2897444A1/en not_active Abandoned
- 2014-01-07 SG SG10201913130PA patent/SG10201913130PA/en unknown
- 2014-01-07 JP JP2015551846A patent/JP6534933B2/ja active Active
- 2014-01-08 AR ARP140100065A patent/AR094389A1/es unknown
- 2014-09-26 NO NO14781027A patent/NO3050055T3/no unknown
-
2015
- 2015-07-07 IL IL239824A patent/IL239824B/en active IP Right Grant
-
2018
- 2018-07-10 HK HK18108963.6A patent/HK1249544A1/en unknown
-
2019
- 2019-05-28 JP JP2019098958A patent/JP6837094B2/ja active Active
-
2022
- 2022-03-03 US US17/686,245 patent/US20220340883A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239824B (en) | Use of inos inhibitors to increase viral survival in culture | |
| IL269662A (en) | Hepatitis C virus inhibitors | |
| IL255045A0 (en) | A crystal of flumioxazin | |
| EP2971014A4 (en) | CELL CULTURE METHODS | |
| EP2971040A4 (en) | CELL CULTURE METHODS | |
| EP2855745A4 (en) | METHODS RELATING TO ADALIMUM AB | |
| PL3591047T3 (pl) | Mieszanki peptydowe do wytwarzania wielowirusowych ctl o szerokiej swoistości | |
| EP2992089A4 (en) | Use of anti-cd47 agents to enhance immunization | |
| EP2844903A4 (en) | TUBES AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| EP2808318A4 (en) | CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF | |
| EP2803657A4 (en) | CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF | |
| IL244453A0 (en) | Methods for determining response to medical treatment | |
| LT2964027T (lt) | Derinių, apimančių klokvintocet-meksilą, panaudojimas augalų derliaus pagerinimui | |
| FR2994974B1 (fr) | Distillation reactive des dso | |
| IL235074A0 (en) | Growth acceleration of babies | |
| IL259184B (en) | Flumioxazin crystal | |
| EP2996716A4 (en) | Correlates of efficacy relating to tumor vaccines | |
| TWM476142U (en) | Culturing device capable of increasing purity of culture | |
| HK1226485A1 (en) | Methods of determining response to therapy | |
| GB201322036D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201310488D0 (en) | New therapeutic uses of enzyme inhibitors | |
| TH1301004837B (th) | วิธีการเพิ่มผลผลิตของน้ำยาง | |
| GB201314498D0 (en) | Improvements to Receivers and Method of Use Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |